Shots:
- Ailux (XtalPi’s subsidiary) has entered into a strategic platform-based collaboration with Eli Lilly to accelerate the discovery & development of bispecific antibodies (bsAbs) for various diseases
- As per the deal, Lilly will nominate an undisclosed number of target pairs for bsAb design & may license Ailux’s platform for internal use. In exchange, Ailux will receive an upfront & near-term payment in the double-digit millions, incl. a platform license option, with the total deal value reaching ~$345M
- Under this deal, Lilly will obtain access to Ailux’s AI-driven bsAb platform that combines structural modeling, generative design, & developability analytics to create therapeutics with novel function, high efficacy, & drug-like properties
Ref: Ailux | Image: Ailux & Eli Lilly | Press Release
Related News:- Merck Signs an R&D Funding Deal with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
